Biotech
Commented by Fabian Lorenz on June 25th, 2025 | 07:30 CEST
BioNTech swallows CureVac! Evotec and Vidac Pharma next? Price driver takeover and Buy recommendation
Is Vidac Pharma about to see another price explosion? Last fall, the share rose by around 200%. Yesterday, there was a "Buy" recommendation. Analysts see potential for growth in this biotech gem. The latest news on the drug candidate VDA 1102 for brain tumors is promising. Could a takeover be on the cards? CureVac's share price has nearly doubled since the beginning of April. BioNTech plans to acquire its mRNA competitor and thus end patent disputes. Evotec is a permanent fixture on the takeover merry-go-round. However, this currently seems to be the only hope for rising share prices. The management's new strategy has not created the hoped-for wave of optimism. Is it still worth buying now?
Read
Commented by Armin Schulz on June 24th, 2025 | 07:30 CEST
Portfolio Doubler with Artificial Intelligence: Novo Nordisk, PanGenomic Health, and Pfizer Ignite the Profit Growth in 2025
According to BlackRock Health Sciences, the global healthcare sector is poised for an unprecedented boom in 2025. After years of volatility driven by the pandemic, the industry is now expected to achieve its highest profit growth in almost two decades - and across the board, not just among pandemic-driven outliers. Digital revolutions such as AI-assisted drug development and telemedicine are accelerating change and creating radically new business models. Those who understand the architects of this transformation will recognize the growth drivers of tomorrow. With this in mind, we take a closer look at three key companies: Novo Nordisk, PanGenomic Health, and Pfizer.
Read
Commented by Stefan Feulner on June 24th, 2025 | 07:25 CEST
Revolution in the pharmaceutical industry – NetraMark beats ChatGPT by a mile
It was a real bombshell when NetraMark announced yesterday, shortly before the US stock market opened, that a preprint published on the arXiv portal shows that the Company's proprietary AI, NetraAI, is not only technologically ahead but also measurably outperforms leading models like ChatGPT and DeepSeek. In the analysis of clinical study data, NetraAI delivers the only statistically valid and medically actionable results. This positions the Canadian company as a potential game changer in a billion-dollar market where traditional machine-learning methods often fall short.
Read
Commented by Nico Popp on June 23rd, 2025 | 07:15 CEST
The next cash cow? Quick profits with NetraMark, Moderna, and BioNTech
Do you remember the vaccine race during the coronavirus pandemic? Back then, the duel between BioNTech and CureVac dominated the stock market. Early investors quickly made a fortune. Now, pandemic winner BioNTech aims to swallow up its Swabian competitor. What does this mean, and where is one of the most fascinating industries headed?
Read
Commented by Fabian Lorenz on June 20th, 2025 | 06:55 CEST
Declaration of war on the pharmaceutical industry? Bayer, Novo Nordisk, and insider tip PanGenomic Health
Has US Health Secretary Robert F. Kennedy Jr. declared war on the traditional pharmaceutical industry? That is certainly what former Trump press secretary and current podcaster Anthony Scaramucci seems to think. The reason for this is the complete overhaul of the US Vaccine Advisory Committee. One company set to benefit from the new US Health Secretary is PanGenomic Health. The Company plans to launch a new digital health and alternative medicine business this year. If it manages to secure even a small share of this billion-dollar market, its share price could multiply. The price target for Novo Nordisk was recently reduced. The stock is working on bottoming out, and there was a success for the blockbuster in the US. Bayer's stock is trending favorably. Regular positive news is currently overshadowing the legal disputes in the US. There was recently some positive news to report there.
Read
Commented by Fabian Lorenz on June 19th, 2025 | 07:05 CEST
Share price speculation thanks to drones and artificial intelligence: Rheinmetall, BioNTech, and NetraMark shares
Drones and artificial intelligence are set to revolutionize entire industries. Listed companies that play a leading role in this transformation hold significant upside potential, such as NetraMark. Using artificial intelligence, the Company helps pharmaceutical and biotech companies shorten development times and reduce costs. NetraMark also aims to help shape industry trends. BioNTech, too, relies on AI for its research, frequently acquiring specialized companies. Perhaps NetraMark will be next? In any case, the Canadians would still be a bargain. Rheinmetall shares, on the other hand, are certainly not cheap. However, the multibillion-euro defense budgets for rearmament in Europe are fueling speculation. In order to be able to deliver not only tanks, howitzers, and ammunition quickly, but also cutting-edge technology, Germany's largest defense contractor is focusing on partnerships. This is evident in its latest partnership, which is expected to enable Rheinmetall to deliver combat and kamikaze drones quickly.
Read
Commented by André Will-Laudien on June 19th, 2025 | 07:00 CEST
Biotech: Weight loss and cancer – Takeovers ahead! Keep an eye on Evotec, Vidac Pharma, Eli Lilly, and Novo Nordisk!
For nearly two years, the biotech sector remained largely stagnant. But in the last few weeks, some heavily bombed-out life science stocks have seen significant gains, and takeovers are back on the agenda. Eli Lilly is acquiring Verve Therapeutics, and BioNTech has finally reached an agreement with CureVac. The carousel is slowly starting to turn, and tensions are rising. New rumors are circulating, especially as major pharma stocks like Eli Lilly and Novo Nordisk are showing negative 12-month performance - despite record highs in the major indices.
What is next?
Commented by Armin Schulz on June 17th, 2025 | 07:25 CEST
Pharmaceutical revolution 2025: Why Novo Nordisk, NetraMark Holdings, and Bayer are doubling their returns through AI efficiency
The pharmaceutical industry is undergoing a digital transformation in 2025. Artificial intelligence is decoding active ingredients in record time, big data is driving personalized therapies, and blockchain is securing supply chains. These technologies are catapulting efficiency skyward and dramatically reducing development costs in a billion-dollar market that is growing steadily due to demographic change. Those who identify the right companies now will benefit from the disruptive wave. Therefore, we look at three companies that could benefit from this change: Novo Nordisk, NetraMark Holdings, and Bayer.
Read
Commented by André Will-Laudien on June 17th, 2025 | 07:05 CEST
Takeovers! A new dawn for biotech companies – Evotec, BioNTech, PanGenomic Health, and CureVac in focus
Many large pharmaceutical companies are facing the "patent cliff" as patents on blockbuster drugs expire, threatening massive revenue losses in the future. To fill these gaps, they are acquiring suitable and innovative biotech companies with promising drug pipelines. Sometimes, however, they simply acquire technologies already worth billions. The current wave of acquisitions in the biotech sector is being driven by a combination of economic pressure, technological change toward AI and digitalization, and a weak financing environment for smaller biotech companies. After years of restraint and high volatility, fundamental valuation factors are back in focus. Investors are returning, creating a prosperous environment for those who jump on the bandwagon in time. We highlight a few ideas.
Read
Commented by Armin Schulz on June 16th, 2025 | 07:10 CEST
Benefit from the biotech boom: Why Evotec, BioNxt Solutions & BioNTech could be the next winners
The biotech sector is pulsating with unique dynamism while traditional markets are faltering. The drivers are billion-dollar acquisitions, groundbreaking research, and strategic alliances. Large pharmaceutical companies are eagerly securing access to innovations. Analysts agree: strong patent portfolios and innovative partnerships are crucial for future growth. These protect valuable therapeutic developments and enable even smaller players to scale globally. For investors, this robust, capital-rich industry offers enormous opportunities. Those who identify the right innovators early on can reap above-average profits. Three companies embody this momentum: Evotec, BioNxt Solutions, and BioNTech.
Read